PRTG (Portage) Long-Term Debt

Graphic logo of Portage Biotech Corp (PRTG)

Portage Biotech Inc. (PRTG) relies on a virtual business model by delegating synthesis and testing to external contractors, making its dependence on outsourcing critical. The market trend regarding long-term debt, which stands at 0.00, highlights liquidity shortage risks and the speculative nature of asset protection in the early stages. At the same time, Portage Biotech Inc. (PRTG) possesses benchmark growth potential, as production costs will become minimal following drug registration.

PRTG Portage Biotech Inc.: Company Long-Term Debts in the range 07/04/2022 - 09/04/2025

Analytical breakdowns for Portage Biotech Inc.

- price and consensus price forecast:
Share Price portagebiotech.com|PRTG - Analyst Consensus Forecast
- market capitalization data:
Market Value Portage Biotech|PRTG - Total Company Value
- book capitalization data:
Accounting Value of a Share Portage Biotech|PRTG - Book Capitalization|Market Capitalization to Book Value Ratio portagebiotech.com|PRTG - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Portage Biotech Inc.|PRTG - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Portage Biotech Corp|PRTG - Company Debts|Debts to Book Value Portage Biotech|PRTG - Company Long-Term Debt|Company Short-Term Indebtedness Portage Biotech
Fundamental valuation:portagebiotech.com (PRTG)
Mass-produced product of Portage Biotech Corp

Asset managers are evaluating the operating model of Portage Biotech Inc. (PRTG) through the lens of its debt load. This metric aggregates obligations with maturities exceeding one year, reflecting the liability structure and credit stability. The trend in the issuer's long-term liabilities demonstrates the cost of borrowed capital used to develop the iNKT-cell platform. Monitoring this indicator allows for a correlation between the costs of remodeling the tumor microenvironment and financial reliability. The result determines the balance between expansion in immuno-oncology and the risk of liquidity shortages.

Competitor analysis

Company Long-Term Indebtedness incyte.com INCY|HCM (HUTCHMED) - Company Long-Term Debts|NUVB: Long-Term Debt|Company Long-Term Debt Day One Bio DAWN|Monopar Corp (MNPR) - Company Long-Term Loans and Borrowings|INBX (Inhibrx Biosciences) - Company Long-Term Debts|Company Long-Term Debts IMAB|Company Long-Term Debt Fennec Pharmaceuticals Inc. (FENC)|Company Long-Term Debt herontx.com HRTX|Company Long-Term Liabilities Nuvectis|Coherus BioSciences - Company Long-Term Loans and Borrowings|CRBP (Corbus Pharmaceuticals) - Company Long-Term Debt|CRDF: Long-Term Debt|Company Long-Term Debt BeyondSpring|BioAtla (BCAB) - Company Long-Term Indebtedness|Company Long-Term Debts LIXT|Company Long-Term Liabilities CTXR|Cellectar Biosciences - Company Long-Term Debt|Long-Term Debt BLRX (biolinerx.com)|Company Long-Term Debt Can-Fite BioPharma Ltd. CANF|Aprea Therapeutics Inc. - Company Long-Term Debt|KZIA (Kazia) - Company Long-Term Debt|SLXN - Long-Term Debt|Company Long-Term Debts NCNA (nucana.com)|Long-Term Indebtedness chimerix.com|Company Long-Term Liabilities CYCC (Cyclacel)|Long-Term Debt G1 Pharma (GTHX)|Kronos Bio Corp (KRON) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings Kintara Pharma KTRA|Company Long-Term Liabilities Oncternal Therapeutics (ONCT)